In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as Janssen’s IL-12/23 inhibitor Stelara, have been leading the U.S. psoriasis biologics market. However, the…
MARKET OUTLOOK Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after the launch of Pfizer’s Jak…
MARKET OUTLOOK SLE is an autoimmune disease that can manifest in many different organs, including the kidneys. Renal inflammation associated with SLE, also known as lupus nephritis, is among the…
Market Outlook In the EU5, access to disease-modifying therapies (DMTs) for the treatment of multiple sclerosis is impacted by multiple factors including specific indication labeling, monitoring…
MARKET OUTLOOK The hospital-treated gram-negative infection (GNI) therapy market is dominated by highly effective, generically available antibiotics. However, the rising prevalence of multidrug-…
MARKET OUTLOOK The hospital-treated gram-negative infection (GNI) therapy market is dominated by highly effective, generically available antibiotics. However, the rising prevalence of multidrug-…
MARKET OUTLOOK The increase in oral oncolytics has fueled an increase in physician dispensing of drugs either from the office or from a pharmacy owned by the practice or hospital, as allowed by…
Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disease characterized by progressive chorea, dystonia, and cognitive decline. Current treatment is entirely focused on…
Market Outlook The most important clinical distinction in the first-line treatment of multiple myeloma is determining whether the patient is eligible to undergo autologous stem-cell…
Market Outlook Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular…
Market Outlook The most important clinical distinction in the first-line treatment of multiple myeloma is determining whether the patient is eligible to undergo autologous stem-cell…
MARKET OUTLOOK Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. Significant…
MARKET OUTLOOK Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. Significant…
MARKET OUTLOOK Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. Significant…
Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by progressive muscle weakness due to the loss of anterior horn motor neurons. Nearly all cases of SMA are caused by…